NHR4 Domain Mutations of ETO Are Probably Very Infrequent in AML1–ETO Positive Myeloid Leukemia Cells

Leukemia - United Kingdom
doi 10.1038/leu.2009.291
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Detection of DNA Rearrangements in the AML1 and ETO Loci and of an AML1/ETO Fusion mRNA in Patients With T(8;21) Acute Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
1993English

Gene Mutation Profile and Risk Stratification in AML1‑ETO‑positive Acute Myeloid Leukemia Based on Next‑generation Sequencing

Oncology Reports
MedicineCancer ResearchOncology
2019English

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML

Cell Reports
BiochemistryGeneticsMolecular Biology
2016English

Targeting the Oligomerization Domain of ETO Interferes With RUNX1/ETO Oncogenic Activity in T(8;21)-Positive Leukemic Cells

Cancer Research
Cancer ResearchOncology
2007English

ETO, but Not Leukemogenic Fusion Protein AML1/ETO, Augments RBP-J /SHARP-Mediated Repression of Notch Target Genes

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2008English

A Histone Acetyltransferase P300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells

PLoS ONE
Multidisciplinary
2013English

The AML1/ETO Target Gene LAT2 Interferes With Differentiation of Normal Hematopoietic Precursor Cells

Leukemia Research
Cancer ResearchOncologyHematology
2014English

The AML1-ETO Fusion Gene and the FLT3 Length Mutation Collaborate in Inducing Acute Leukemia in Mice

Journal of Clinical Investigation
Medicine
2005English

Monitoring of Minimal Residual Disease (MRD) by Real-Time Quantitative Reverse Transcription PCR (RQ-RT-PCR) in Childhood Acute Myeloid Leukemia With AML1/ETO Rearrangement

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy